Home Featured Page 26

Featured

Latest

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

Book Club! Built To Burn: Tales of the Desert Carnies of...

TK Wonder & Cipriana Quann on Sisterhood, Survival, and Psychedelic Healing

The Psychedelic Practitioner: Issue 1

Psychedelic Investor Survey Q3 2025

Ivar Goksøyr — Wounded Healers, Inner Intelligence & Bringing MDMA Training...

MDMA-Assisted Therapy & The Wounded Healer: Training for Mental Health Professionals

MDMA-Assisted Therapy for the Wounded Healer: Help fund a pioneering study!

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

Book Club! Built To Burn: Tales of the Desert Carnies of...

Book Club – Trip Sitting

TK Wonder & Cipriana Quann on Sisterhood, Survival, and Psychedelic Healing

The Psychedelic Practitioner: Issue 1

Psychedelic Investor Survey Q3 2025

Ivar Goksøyr — Wounded Healers, Inner Intelligence & Bringing MDMA Training...

MDMA-Assisted Therapy & The Wounded Healer: Training for Mental Health Professionals

MDMA-Assisted Therapy for the Wounded Healer: Help fund a pioneering study!

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY